Cellectar Biosciences, Inc. Restricted Cash and Cash Equivalents, Noncurrent
Cellectar Biosciences, Inc. (CLRB) had Restricted Cash and Cash Equivalents, Noncurrent of $0 as of 2013-12-31, per its 10-K filed 2014-03-19.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:RestrictedCashAndCashEquivalentsNoncurrent · last filed 2014-03-19
- 2013-12-31: Restricted Cash and Cash Equivalents, Noncurrent $0.00.
- 2013-09-30: Restricted Cash and Cash Equivalents, Noncurrent $0.00.
- 2013-06-30: Restricted Cash and Cash Equivalents, Noncurrent $1.88M.
- 2013-03-31: Restricted Cash and Cash Equivalents, Noncurrent $1.88M.
| Period end | Restricted Cash and Cash Equivalents, Noncurrent |
|---|---|
| 2013-12-31 | $0.00 10-K · filed 2014-03-19 |
| 2013-09-30 | $0.00 10-Q · filed 2013-11-13 |
| 2013-06-30 | $1.88M 10-Q · filed 2013-08-12 |
| 2013-03-31 | $1.88M 10-Q · filed 2013-05-15 |
| 2012-12-31 | $2.00M 10-K · filed 2014-03-19 |
| 2011-12-31 | $0.00 10-K · filed 2013-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |